Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 7590 results
Filters: First Letter Of Last Name is K  [Clear All Filters]
Found 7590 results.

Absorptiometry, Photon

Mulligan K, Parker RA, Komarow L, et al. "Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial." J. Acquir. Immune Defic. Syndr.. 2006;41(5):590-7.
Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
McComsey GA, Kendall MA, Tebas P, et al. "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV." AIDS. 2007;21(18):2473-82.
Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
Erlandson KM, Kitch D, Tierney C, et al. "Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density." AIDS. 2013;27(13):2069-79.

Accidental Falls

Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.

Acquired Immunodeficiency Syndrome

Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Grady BJ, Samuels DC, Robbins GK, et al. "Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384." J. Acquir. Immune Defic. Syndr.. 2011;58(4):363-70.
Su Z, Gulick RM, Krambrink A, et al. "Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211." J. Infect. Dis.. 2009;200(11):1724-8.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. "Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms." AIDS. 2013;27(6):967-72.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Wohl DA, Kendall MA, Feinberg J, et al. "The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit." PLoS ONE. 2013;8(11):e78676.
Wohl DA, Kendall MA, Andersen J, et al. "Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030." HIV Clin Trials. 2009;10(3):143-52.
Koelsch KK, Liu L, Haubrich R, et al. "Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro." J. Infect. Dis.. 2008;197(3):411-9.
Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Williams P, Wu J, Cohn S, et al. "Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution." HIV Med.. 2009;10(5):290-301.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Gange SJ, Kitahata MM, Saag MS, et al. "Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)." Int J Epidemiol. 2007;36(2):294-301.

Pages